# A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

> **NCT06939283** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Werewolf Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** WTX-330

## Key facts

- **NCT ID:** NCT06939283
- **Lead sponsor:** Werewolf Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2028-08
- **Final completion:** 2028-08
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06939283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06939283, "A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06939283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*